We are delighted to announce our collaboration with Gasgon Medical for the development of a novel device for reducing risks for air embolism and IV-line dislodgement. This can strongly increase the safety for patients and nurses during IV chemotherapy therapy at home. There is an increasing demand for intravenous (IV) oncology therapy in a homecare setting. From a healthcare system point of view, up to 90% of the costs could be cut comparing IV therapy given at home to the same care conducted in a hospital setting. From the patient perspective, several studies have shown that the overall experience of treatment is much improved in a homecare setting without a lesser clinical outcome. A proof-of-concept device to address these specific risks has been developed. The disposable closed system device consists of an automatic vent to remove air combined with ReLink® that disconnects when the IV line is forcefully pulled. The vent eliminates the need for manual removal of air bubbles, thus reducing drug exposure and disruption to flow rates. ReLink® has valves that seal the system on both sides to retain all liquids in the event of a pulled IV line, reducing injury from dislodgement and drug exposure. Feasibility testing of the device has shown a 99.97% success at air removal compared to standard IV delivery methods and reduction in dislodgment frequency of 92%. An abstract based on the initial studies has also been published in the Annals of Oncology.
R.S. Bejhed: Leadership role, Shareholder/Stockholder/Stock options, Full/Part-time employment, Officer/Board of Directors: Tada Medical AB. V.P. Forde: Leadership role, Shareholder/Stockholder/Stock options, Full/Part-time employment, Officer/Board of Directors: Gasgon Medical.